Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Click Therapeutics, Inc.
With
Boehringer Ingelheim
The purpose of the proposed study is to evaluate the efficacy and safety of two prescription digital therapeutics as an adjunct treatment to SOC in participants 18 years of age or older diagnosed with experiential negative symptoms of schizophrenia.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A participant will be eligible for entry into the study if all of the following criteria are met:
1. Has a primary diagnosis of schizophrenia.
2. Is on a stable dose of antipsychotic medication(s).
3. Has obtained an average score of ≥2 (moderate to severe) in at least two of the three CAINS-MAP domains (Social, Work, or Recreational).
You may not be if
A participant will not be eligible for study entry if any of the following criteria are met:
1. Is currently treated with more than two antipsychotic medications (including more than two dosage forms).
2. Meets DSM-5, for diagnoses not under investigation.
